A5030633140- Acute Kidney Injury Research
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Cardiac Arrest and Resuscitation
- Immunodeficiency and Autoimmune Disorders
- Sepsis Diagnosis and Treatment
- Pharmaceutical Practices and Patient Outcomes
- Disaster Response and Management
- Healthcare professionals’ stress and burnout
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Opioid Use Disorder Treatment
- Lipoproteins and Cardiovascular Health
- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Poisoning and overdose treatments
- Potassium and Related Disorders
Premier Research Group
2022-2024
Introduction: The burden of persistent (≥3 days) severe AKI (PS-AKI) is poorly described among inpatients with stage 2–3 in the ward or ICU. Quantification could motivate targeted interventions to decrease duration these high-risk patients. Methods: This retrospective cohort study included adult patients discharged from January 1, 2017, December 31, 2019, US hospitals PINC AI Healthcare Database. Patients KDIGO 2 3 AKI, length stay ≥3 days, serum creatinine measures, and no history renal...
Real-world comparison of RRT modality on dependence at 90 days postdischarge among ICU patients discharged alive after for acute kidney injury (AKI). Using claims-linked to US hospital discharge data (Premier PINC AI Healthcare Database [PHD]), we compared continuous renal replacement therapy (CRRT) vs. intermittent hemodialysis (IHD) AKI in adult from January 1, 2018 June 30, 2021. was defined as ≥2 treatments the last 8 days. Between-group differences were balanced using inverse...
Key Points Among hospitalized patients with stage 2/3 AKI, persistent severe acute kidney injury (PS-AKI) is associated significantly longer length of stay (LOS) and higher costs during index hospitalization 30 days postdischarge. Relative differences in LOS for PS-AKI versus NPS-AKI were similar intensive care (ICU) non-ICU patients. Preventing among AKI may reduce hospital costs. Background Persistent worse clinical outcomes, but there are no data on PS-AKI. We compared health resource...
The 2018 American Heart Association (AHA)/American College of Cardiology (ACC)/Multisociety blood cholesterol guidelines recommend clinicians consider adding non-statin therapy for patients with very high-risk (VHR) atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein (LDL-C) ≥ 70 mg/dl while receiving maximally tolerated statins. However, according to a recent study, only 17.1% established ASCVD received appropriate lipid-lowering (LLT) intensification. Here, we...
7052 Background: Bruton tyrosine kinase inhibitors (BTKis) are effective treatments for various B-cell malignancies including CLL/SLL but known to be associated with increased bleeding risk. Current evidence indicating this association has largely been demonstrated in clinical trial research. However, risk real-world patients, who often sicker more comorbidities requiring anticoagulant (AC) or antiplatelet (AP) use is not well described. This study aimed assess the prevalence of AC/AP and...
Background: In hospitalized patients with COVID-19, acute kidney injury (AKI) is associated higher mortality, but data are lacking on healthcare resource utilization (HRU) and costs related to AKI, community-acquired AKI (CA-AKI), hospital-acquired (HA-AKI). Objectives: To quantify the burden of CA-AKI, HA-AKI among inpatients COVID-19. Methods: This retrospective cohort study included COVID-19 discharged from US hospitals in Premier PINC AI™ Healthcare Database April 1–October 31, 2020,...
Background: In hospitalized patients with COVID-19, acute kidney injury (AKI) is associated higher mortality, but data are lacking on healthcare resource utilization (HRU) and costs related to AKI, community-acquired AKI (CA-AKI), hospital-acquired (HA-AKI). Objectives: To quantify the burden of CA-AKI, HA-AKI among inpatients COVID-19. Methods: This retrospective cohort study included COVID-19 discharged from US hospitals in Premier PINC AI™ Healthcare Database April 1–October 31, 2020,...
Background: In hospitalized patients with COVID-19, acute kidney injury (AKI) is associated higher mortality, but data are lacking on healthcare resource utilization (HRU) and costs related to AKI, community-acquired AKI (CA-AKI), hospital-acquired (HA-AKI). Objectives: To quantify the burden of CA-AKI, HA-AKI among inpatients COVID-19. Methods: This retrospective cohort study included COVID-19 discharged from US hospitals in Premier PINC AI™ Healthcare Database April 1–October 31, 2020,...